BA
HAE icon

Boston Advisors’s Haemonetics HAE Stock Holding History

Boston Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-39,898
Closed -$2.92M – 657
2018
Q1 		$2.92M Sell
39,898
-7,827
-16% -$537K 0.07% 242
2017
Q4 		$2.77M Sell
47,725
-3,100
-6% -$163K 0.06% 263
2017
Q3 		$2.28M Buy
50,825
+23,180
+84% +$963K 0.05% 278
2017
Q2 		$1.09M Buy
+27,645
New +$1.14M 0.03% 367

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Boston Advisors's HAE Position: Q2 2018 in Review

Boston Advisors sold out of Haemonetics (HAE) in Q2 2018, closing a stake of 39,898 shares — an estimated $2.92M sold.

Boston Advisors first reported a position in HAE in Q2 2017 and held it in 4 quarters. The position peaked at $2.92M in Q1 2018. 293 funds tracked by Wall St. Rank hold HAE as of Q2 2018.

  • Boston Advisors reported no remaining Haemonetics position as of Q2 2018 after selling out during the quarter.
  • Boston Advisors sold 39,898 Haemonetics shares in Q2 2018, an estimated $2.92M.
  • Boston Advisors first reported a position in Haemonetics in Q2 2017 and held it in 4 quarters.
  • Boston Advisors's Haemonetics position peaked at $2.92M in Q1 2018.
  • 293 funds tracked by Wall St. Rank held Haemonetics as of Q2 2018.

Based on Boston Advisors's 13F filing for Q2 2018, filed 18 Jul 2018.